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Abstract
Background: Avian leukosis virus (ALV) is a major infectious disease that impacts the poultry industry worldwide.
Despite intensive efforts, no effective vaccine has been developed against ALV because of mutations that lead to
resistant forms. Therefore, there is a dire need to develop antiviral agents for the treatment of ALV infections and
RNA interference (RNAi) is considered an effective antiviral strategy.
Results: In this study, the avian leukosis virus subgroup J (ALV-J) proviral genome, including the gag genes, were
treated as targets for RNAi. Four pairs of miRNA sequences were designed and synthesized that targeted different
regions of the gag gene. The screened target (i.e., the gag genes) was shown to effectively suppress the replication
of ALV-J by 19.0-77.3%. To avoid the generation of escape variants during virus infection, expression vectors of
multi-target miRNAs were constructed using the multi-target serial strategy (against different regions of the gag,
pol, and env genes). Multi-target miRNAs were shown to play a synergistic role in the inhibition of ALV-J
replication, with an inhibition efficiency of viral replication ranging from 85.0-91.2%.
Conclusion: The strategy of multi-target miRNAs might be an effective method for inhibiting ALV replication and
the acquisition of resistant mutations.
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Background
Avian leukosis (AL) is the general term for a variety of
neoplastic diseases of poultry caused by the Alpharetro-
virus, Avien leukosis virus (ALV). ALV has been classi-
fied into 10 subgroups, designated A-J. The subgroup J
virus (ALV-J) is a relatively new strain of ALV that was
isolated from Dorking fowl in the early 1990s [1]. ALV
is an RNA virus with a genome of approximately 7.6 kb.
The proviral genome of ALV-J contains three major
genes, gag, pol,a n denv, which encode the viral struc-
tural proteins, RNA-dependent DNA polymerase, and
the envelope glycoprotein, respectively.
RNA interference (RNAi) is a simple and effective tool
for silencing target genes that involves endogenous or
exogenous double-stranded RNA (dsRNA)-mediated
degradation of the specific mRNA sequences. The main
nucleic acid molecules that induce gene silencing are
small interfering RNA (siRNA) and microRNA
(miRNA), where the siRNAs mediate specific mRNA
degradation, whereas miRNA inhibits specific mRNA at
the translational level. Both of these biological processes
are considered key methods of modulating host gene
expression, and these two molecules are also involved in
antiviral and transposon silencing pathways.
The RNAi strategy has been successfully applied to
the inhibition of viral replication. It has been demon-
strated that some genes inhibited by siRNAs, such as
p24, vif, nef, tat,a n drev, can block Human immunode-
ficiency virus (HIV) replication in cells [2]. The infection
of cells by HIV may be hindered by inhibiting the
expression of the HIV receptors CD4 and CD8a, their
coreceptors CXCR4 or CCR5, or the virus Gag struc-
tural protein [3]. In some studies, transfection of siRNA
designed to target C virus (HCV) remarkably inhibited
the expression of virus-specific proteins and protected
cells against HCV RNA, in vitro [4,5]. In another study,
Hepatitis B virus (HBV) replication was successfully
inhibited after plasmid expression of HBV siRNA trans-
fected into mouse liver [6]. Hu et al. [7] adopted siRNA
designed against the ALV gag gene and demonstrated
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any medium, provided the original work is properly cited.significantly reduced virus replication. Chen et al. [8]
indicated that ALV-B replication was significantly inhib-
ited after knockdown of the ALV-B tvb and env genes.
Although siRNAs have been widely used as gene-silen-
cing molecules, the intrinsic drawbacks of siRNA meth-
odology have been revealed. Off-target effects may be
produced where siRNA function must be fully and com-
pletely complementary to the target sequence; if the
virus mutates, siRNA will produce off-target effects.
Other drawbacks include the elicitation of the interferon
response and interference with endogenous miRNA bio-
genesis. The unique biogenesis and mechanism of action
of miRNA do reduce the likelihood of these problems.
Despite these problems, the RNAi strategy remains an
attractive option for antiviral therapy and for the func-
tional analysis of genes for several reasons. First, RNAi
has sequence specificity. Second, the application of
multi-series RNAi can target different genes or
sequences simultaneously and hence can minimize the
possibility of the virus acquiring mutations that confer
resistance. Third, RNAi can be transmitted from non-
pathogenic viruses to pathogenic viruses. Finally, due to
its sequence specificity, siRNA designed against a virus
can only inhibit that virus, leaving vaccine strains unaf-
fected. To ensure a high level of RNAi gene silencing,
multiple miRNAs can be designed. These can be trans-
fected into cells using the same transfer medium, and
by targeting different sequences, mutation of the target
virus, and therefore the probability of evasion from the
silencing effect of the miRNA is minimized.
ALV, especially ALV-J, brings about enormous eco-
nomic losses in the poultry industry. The virus has
rapidly spread worldwide and transmits both vertically
and horizontally. However, chicks are immunologically
tolerant to ALV infection. Unfortunately, to date, no
effective vaccine has been developed against ALV. In
this study, we used RNAi technology to inhibit ALV
replication and screened the effective target sites for
their ability to inhibit ALV replication at a cellular level.
Our findings could pave the way for anti-ALV gene
screening and the development of disease resistance.
Materials and methods
Viruses and cells
The SD strains of ALV-J were isolated from poultry in
Shandong, China, and stored at the Harbin Veterinary
Research Institute (Harbin, China), a Key State Labora-
tory. The DF-1 cell lines [9] were provided by Zhigao
Bu at the Harbin Veterinary Research Institute (Harbin,
China).
Reagents
The linearized the pcDNA6.2-GW/EmGFP-miR eukar-
yotic expression vector, Escherichia coli TOP10 cells
and the Lipofectamine 2000 transfection reagent were
purchased from Invitrogen (Carlsbad, CA, USA). Ligase
and reverse transcriptase were purchased from TaKaRa
(Dalian, China). The fluorescence quantitative PCR kit
was purchased from BIOER Technology (Hangzhou,
China). The plasmid extraction kit and the viral RNA
extraction kit were purchased from Shanghai Watson
Biotech (Shanghai, China). The goat anti-mouse IgG/
fluorescein isothiocyanate (FITC) antibody and the
horseradish peroxidase-labeled goat anti-mouse IgG
were purchased from Zhongshan Goldbridge Biotech-
nology (Beijing, China). The anti-ALV-J monoclonal
antibody JE-9 was kindly provided by Professor Qin
Aijian (Yangzhou University, China). All other chemicals
were of analytical reagent grade.
Design and construction of miRNA expression vector
Design of miRNA
Four pairs of miRNAs sequences were designed against
the conserved regions of the gag gene (NC-015116 gag)
using online software http://rnaidesigner.invitrogen.com/
rnaiexpress/ (Table 1). Designed miRNA sequences were
synthesized by Shanghai Health Bioengineering (China).
Double-stranded oligonucleotide encoding pre-miRNA
sequence were annealed and inserted into the linearized
expression vector, pcDNA6.2-GW/EmGFP-miR (5 ng/
μL), to construct recombinant plasmids containing the
target miRNAs, designated mi-gag1318, mi-gag1365, mi-
gag1623, mi-gag1971. All recombinant plasmids have
been sequenced to confirm the sequences inserted.
Construction of miRNA expression vectors in series
Two tandem plasmids were constructed based on the mi-
gag1318 plasmid backbone. After BglI and XhoI digestion
of mi-gag1318, the miRNA sequence of the pol gene (NC-
015116 pol), mi-pol2516 (constructed previously, manu-
script submitted), was digested with SalIa n dBglI, and
ligated to mi-gag1318. The tandem plasmid consisting of
mi-gag1318 and mi-pol2516 was designated mi-g1318-
p2516. The mi-g1318-e1384 (env gene: NC-015116 env)
and mi-p2516-e1384 plasmids were constructed in the
same way. Plasmids were linearized and used to transform
E. coli TOP10. Positive clones were selected and verified
by digestion with XhoIa n dSalI and sequencing. Similarly,
based on the recombinant plasmid mi-g1318-p2516 back-
bone, a tandem plasmid consisting of mi-gag1318, mi-
pol2516 and mi-env1384 was constructed in the same way
and designated mi-g1318-p2516-e1384. Positive clones
were verified by double digestion with XhoIa n dSalI and
sequencing.
Transfection of recombinant plasmid and
preparation of ALV
DF-1 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 100 U/mL of penicillin
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serum (PAA GOLD, Austria). Twenty-four hours before
transfection, cells that had grown to 70% confluence
were used to inoculate cell culture plates at a density of
3-5 × 10
5. When the cells had grown to 80% confluence,
they were transfected with the RNAi expression plasmid
using Lipofectamine 2000. Six hours later, the culture
fluid was changed DMEM and serum containing 5%
fetal calf serum, without antibiotics. After incubation at
37°C and 5% CO2 for 12 h, the transfection efficiency
was determined by the expression of green fluorescent
protein observed using fluorescence microscopy. Trans-
fected cells were inoculated with 100 50% tissue culture
infectious doses (TCID50) of ALV-J. The culture med-
ium was obtained 72 h after viral infection, and the
inhibitory effect was detected by an indirect immuno-
fluorescence assay (IFA), western blotting, and real-time
PCR. In this study, the negative control group that was
not administered plasmid, the null vector control group
and the test groups were randomized for analysis.
Determination of ALV-J titer
Strain SD was inoculated into DF-1 cell culture bottles,
freeze-thawed three times and then centrifuged at 7000
× g and 4°C for 5 min. The supernatant was collected
and 10-fold serially diluted to 10
-8 and then inoculated
into 96-well plates along with DF-1 cells. Four parallel
well were created in each gradient. After incubation for
5 days, cells were fixed by cooling in methanol at -20°C
for 30 min, and then washed three times with phosphate
buffered saline containing 0.05% Tween 20 (PBST) for
10 min each. ALV-J specific monoclonal antibody JE-9
was diluted 1:200 and 100 μL was added to each well.
The cells were incubated at 37°C for 1 h and washed
with PBST three times, for 10 min each. The secondary
antibody, goat anti-mouse IgG/FITC, was added at a
dilution of 1:200, and the cells were incubated at 37°C
for 45 min away from the light. The cells were then
washed with PBST five times, for 10 min each. The
number of fluorescent cells per well were counted using
a fluorescence microscope, and the TCID50 was
calculated using the Reed-Muench method [10]. There-
fore, the toxic potency of the virus was determined to
be 10
5.2 TCID50/mL.
Expression of the envelope glycoprotein by IFA
Virus strain SD was used to inoculate DF-1 cells trans-
fected with recombinant plasmid using the method
described above. After 5 days incubation, cells were
treated with the fluorescent secondary antibody, rhoda-
mine-labeled goat anti-mouse IgG/TRITC, as described
above. The results were photographed using a fluores-
cence microscopy.
Western blot
At about 72 h after transfection with the miRNA recom-
binant plasmid, DF-1 cells were collected and the residual
supernatant fluid was washed with PBS. Total protein
was extracted using the total protein extraction kit (Best-
Bio, China) and quantitated using a spectrophotometer.
Sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE; 10%) was performed using a sample
volume of 300 μg per well. Samples were transferred to
nitrocellulose membrane after separation, blocked at 4°C
overnight and then washed with PBST three times, for 10
min each. ALV-J-specific monoclonal antibody JE-9 was
added and the cells were incubated at 37°C for 1 h and
mouse anti-chicken glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) monoclonal antibodies were added
and incubated at room temperature for 1 h, followed by
three washes with PBST for 10 min each. Horseradish
peroxidase-labeled anti-mouse secondary antibody was
added and cells were incubated at 37°C for 45 min. After
washing with PBST five times, 10 min each wash, the
cells were stained with 3,3’ diaminobenzidine (DAB, 6
mg, 10 mL TBS, 0.1 mL 3% H2O2) and then scanned
using the gel imaging system AlphaImager HP.
Quantitative PCR
Using sequences of the ALV gag genes published in the
GenBank database (NC-015116), pairs of primers were
designed using the Oligo 6 primer design software to
Table 1 Oligonucleotide sequences of pre-miRNAs
Sequence (5’ to 3’)
mi-gag1318 TGCTGTTGATCACAAGACTGGCTGATGTTTTGGCCACTGACTGACATCAGCCACTTGTGATCAA
CCTGTTGATCACAAGTGGCTGATGTCAGTCAGTGGCCAAAACATCAGCCAGTCTTGTGATCAAC
mi-gag1365 TGCTGTAGTGATTAAGACAGAGGGACGTTTTGGCCACTGACTGACGTCCCTCTCTTAATCACTA
CCTGTAGTGATTAAGAGAGGGACGTCAGTCAGTGGCCAAAACGTCCCTCTGTCTTAATCACTAC
mi-gag1623 TGCTGATCATTGCGGAACAGCTATTGGTTTTGGCCACTGACTGACCAATAGCTTCCGCAATGAT
CCTGATCATTGCGGAAGCTATTGGTCAGTCAGTGGCCAAAACCAATAGCTGTTCCGCAATGATC
mi-gag1971 TGCTGTTATGTCTCCCTCAGACTTATGTTTTGGCCACTGACTGACATAAGTCTGGGAGACATAA
CCTGTTATGTCTCCCAGACTTATGCAGTCAGTGGCCAAAACATAAGTCTGAGGGAGACATAAC
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a pair of ALV-J specific primers was also synthesized.
Two pairs of target genes and the b-actin gene were
amplified by PCR using the SD cDNA as a template
(Table 2).
The cDNAs amplified using the gag, ALV-specific, and
b-actin primers were cloned into vector pMD-18-T and
used to transform competent E. coli DH5a cells. Positive
clones were isolated and verified by colony PCR and
sequencing, and designated pMT-G and pMT-ALV,
respectively. The concentration and purity of verified
plasmids were determined according to the formula:
copy number = (mass/molecular weight) ×6.0 × 10
23.
Extracted plasmids were then ten-fold serially diluted
and used as temples for quantitative PCR amplification
and delineation of quantitative PCR standard curves.
Total RNA was extracted from viruses and cells 72 h
after the infection of DF-1 cells with ALV-J using Tri-
zol, according to the manufacturer’s instructions. RNA
concentration and purity was determined by measuring
optical density (OD) at wavelengths of 260 and 280
nm using a standard spectrophotometer. The OD260/
OD280 ratios were more than 1.8 for all samples.
Quantitative PCR was performed in a LightCycler 480
Real-Time PCR System, for the gag and ALV-specific
genes using the SYBR GREEN kit (SYBR
® Premix Ex
Taq™, TaKaRa, Dalian, China) and the primers are
listed in Table 1. Amplification was carried out in a 20
μl reaction mixture containing 10 μlS Y B R
® Premix Ex
Taq™2×, 0.2 μM concentration of each primer, 1 μl
cDNA. The reaction procedure was 95°C 10 s, followed
by 40 cycles at 95°Cfor 5 s and 60°C for 40 s. The
number of target genes in different samples was deter-
mined according to the standard curve after the reac-
tion. Meanwhile, the copy number of the b-actin gene
was also determined by quantitative PCR. To confirm
specific amplification, melting curve analysis was
performed.
Data analysis
Experiments were repeated three times and values were
expressed as means ± standard deviation (SD). The t-
test was performed using the SPSS 13.0 statistical
software (version 13.0; SPSS, USA). Differences were
considered statistically significant when p < 0.05.
Results
Envelope protein expression
As shown in Figure 1a and 1b, IFA revealed that the
recombinant plasmids, mi-gag1318 and mi-gag1365, sig-
nificantly reduced the fluorescence intensity. The tan-
dem plasmids, mi-g1318-p2516, mi-g1318-e1384, mi-
p2516-e1384 and mi-g1318-p2516-e1384, also signifi-
cantly inhibited the fluorescence intensity (Figure 2a
and 2b) compared with the negative control group.
However, no significant differences were detected
among other groups compared with the negative control
group and the null vector group.
Western blot analysis of the ALV-J envelope glycoprotein
JE-9 is an anti-ALV-J envelope glycoprotein monoclonal
antibody that specifically identifies a protein with a
molecular weight of 90-94 kDa. As detected by western
blot analysis (Figure 3a, b), the recombinant mi-gag1318
and mi-gag1365 plasmids decreased ALV-J envelope gly-
coprotein expression significantly, while there were no
significant differences determined between the remain-
ing groups and the negative control or null vector
groups. Transfection of the tandem plasmids into DF-1
cells significantly decreased the expression of the ALV-J
envelope glycoprotein, indicating that ALV-J could inhi-
bit plasmid replication.
Quantitative PCR of ALV-J mRNA
Expression of the gag gene in cells transfected with plas-
mids mi-gag1318 and mi-gag1365 differed significantly
from the negative control group and the null vector
control group (P < 0.05), while expression in cells trans-
fected with plasmids mi-gag1623 and mi-gag1971 did
not differ significantly from that in the negative control
and null vector control groups (P > 0.05) (Table 3). The
use of tandem plasmids indicated significant inhibition
of the expression of the ALV-J envelope glycoprotein in
DF-1 cells (85-91.2%), and the rate of inhibition was
highest with plasmid mi-g1318-p2516-e1384 (91.2%)
(Table 4).
Table 2 Primers used to amplify target genes
Target gene (Accession number) Primer sequence Product size (bp) Annealing Temperature (°e)
Gag Forward TCAGGACCAAGGGCTTAC 174 55.2
Reverse CTGCCGCTATAACCGTCTG
ALV specific primer Forward TCAGGACCAAGGGCTTAC 545 55.0
Reverse CTGCCGCTATAACCGTCTG
b-actin Forward TCCCTGTATGCCTCTGGTC 250 55.0
Reverse TCTCTCTCGGCTGTGGTGG
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Page 4 of 9Figure 1 ALV-J replication. (A) Cells transfected with the recombinant plasmid pMD-G and their inhibitory effects against ALV-J, as determined
by the IFA. (B) The fluorescence intensity of cells transfected with the recombinant plasmid pMD-G and their inhibitory effects against ALV-J, as
determined by the IFA. Data are presented as means±S.E.M. of three independent experiments, each performed in triplicate. *Statistically
significant differences compared with negative controls (P<0.05).
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Page 5 of 9Figure 2 Inhibition of ALV-J replication by miRNA. (A) Cells transfected with the recombinant serial miRNA plasmids and their inhibitory
effects against ALV-J, as determined by the IFA. (B) The fluorescence intensity of cells transfected with the recombinant serial miRNA plasmids
and their inhibitory effects against ALV-J, as determined by the IFA. Data are presented as means±S.E.M. of three independent experiments, each
performed with triplicate samples. *Statistically significant differences compared with negative controls (P<0.05).
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Accumulating evidence suggests that RNAi can inhibit
viral replication in vivo and in vitro. RNAi technology
have been applied in numerous studies including those
for HBV [11], HCV [12], HIV-1 [13], influenza virus A
[14], aphthovirus of cattle [15,16], and severe acute
respiratory syndrome (SARS) virus [17] infections. RNAi
has been used to suppress the replication of herpes-
viruses, including Murine herpesvirus 68 [18], Herpes
simplex virus-1 [19], Human cytomegalovirus [20], and
Duck herpesvirus [21].
The ALV-J genome contains a gene arrangement of
LTR-leader-gag-pol-env-LTR. The gag and pol genes are
highly conserved, sharing 96-97% homology in ALV-J,
in contrast to subgroups A, C, and D. The pol gene
mainly encodes the reverse transcriptase (RT; P68) and
viral integrase (IN; P32). RT is responsible for the pro-
duction of proviral DNA using viral RNA as a template,
while IN is involved in the integration of proviral DNA
into the host genome. The pol gene is necessary for
reverse transcription of the RNA genome and the gen-
eration of viral DNA, and it is a key to the insertion of
the viral genome into the host genome. RNAi has been
applied to the inhibition of ALV replication by a num-
ber of research groups. Chen et al. [8] successfully
inhibited ALV-B replication induced by a retroviral vec-
tor by targeting the miRNA of the ALV-B env gene and
its receptor encoded by the tvb gene.
By constructed an miRNA expression vector targeting
the ALV-J gag g e n e ,w ed e m o n s t r a t e dt h a tm i - gag1318
and mi-gag1365 could significantly reduce the expres-
sion of target gene mRNA and envelope glycoprotein at
a cellular level, with the highest inhibition rate of 77.3%
being observed with mi-gag1318. These results showed
that miRNA expression could inhibit the duplication of
the target gag gene, with mi-gag1318 having the highest
inhibitory effect. Accordingly, the miRNA of the gag tar-
get genes could successfully inhibit ALV-J replication.
Thus, the successful construction of a eukaryotic expres-
sion vector would contribute to the selection and propa-
gation of an anti-ALV related gene.
In previous studies, RNAi strategies have been suc-
cessfully employed experimentally to inhibit virus repli-
cation. Hu et al. [7] showed that by electroporation into
chicken embryos, siRNA containing ALV gag sequences
effectively slowed down virus propagation. In the cur-
rent study, the miRNA target gag1318 was selected that
resulted in significant inhibitory effects on ALV-J repli-
cation. These miRNAs were grouped in pairs or
together, and the tandem multi-target miRNAs target
Figure 3 ALV-J envelope glycoprotein expression of DF-1 cells in each in of the groups. (A) Western immunoblot of infected culture
treated with miRNA. Lane M: protein ladder; lane 1: mi-gag1318; lane 2: mi-gag1356; lane 3: mi-gag1623; lane 4: mi-gag1971; lane 5: negative
control; lane 6: null vector control. (B) Western immunoblot of infected cultures treated with miRNA. Lane M: protein ladder; lane 1: mi-g1318-
e1384; lane 2: mi-p2516-e1384; lane 3: mi-g1318-p2516; lane 4: mi-g1318-p2516-e1384; lane 5: negative control; lane 6: null vector control.
Table 3 Quantitative PCR of the miRNA-targeted gag gene inhibiting ALV-J
Group mRNA levels of
gag
mRNA levels of b-
actin
mRNA levels of target gene by b-actin
normalization
Rates of viral suppression
(%)
p-
values
mi-gag1318 1.05 ± 0.11 3.21 ± 0.12 0.327 77.3* 0.01
mi-gag 1365 1.10 ± 0.12 3.14 ± 0.15 0.3350 65.0* 0.02
mi-gag 1623 2.81 ± 0.11 3.49 ± 0.16 0.805 19.5 0.06
mi-gag 1971 3.12 ± 0.17 3.85 ± 0.16 0.810 19.0 0.07
Negative
control
3.15 ± 0.12 3.14 ± 0.12 1. 00 0 0
Vector control 3.62 ± 0.14 3.70 ± 0.12 0.978 0 0
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mi-g1318-p2516-e1384 were co-expressed, reducing the
probability of evasion from the silencing effect of the
miRNA due to virus mutation. When multiple miRNAs
were expressed simultaneously, gene silencing was
shown to be more effective. Tandem plasmids were
transfected into DF-1 cells and then infected with ALV-
J. IFA, western blotting, and quantitative PCR were used
to evaluate the inhibiting effects on ALV-J replication at
the cellular level. The results verified that all of the tan-
dem plasmids could effectively inhibit the replication of
ALV in DF-1 cells, with an inhibition efficiency of 85-
91.2%. The enhanced inhibitory effects conferred by the
multi-target miRNA expression plasmids demonstrated
that the multi-target miRNAs could inhibit ALV
synergistically.
These studies successfully identified targets capable of
inhibiting the replication of ALV-J and are likely to be
good candidates for the development of miRNA-based
vaccines. The current study showed that the strategy of
using multi-target miRNAs might be an effective
method for inhibiting viral replication and for the acqui-
sition of resistant mutations.
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